Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Change in Acquisitions & Divestments: 2022-2024

Historic Change in Acquisitions & Divestments for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Dec 2024 value amounting to $314.5 million.

  • Day One Biopharmaceuticals' Change in Acquisitions & Divestments fell 458.55% to -$425.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $206.5 million, marking a year-over-year decrease of 13.07%. This contributed to the annual value of $314.5 million for FY2024, which is 45.35% down from last year.
  • According to the latest figures from FY2024, Day One Biopharmaceuticals' Change in Acquisitions & Divestments is $314.5 million, which was down 45.35% from $575.4 million recorded in FY2023.
  • Over the past 5 years, Day One Biopharmaceuticals' Change in Acquisitions & Divestments peaked at $575.4 million during FY2023, and registered a low of $139.2 million during FY2022.
  • For the 3-year period, Day One Biopharmaceuticals' Change in Acquisitions & Divestments averaged around $343.0 million, with its median value being $314.5 million (2024).
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first surged by 313.52% in 2023, then crashed by 45.35% in 2024.
  • Yearly analysis of 3 years shows Day One Biopharmaceuticals' Change in Acquisitions & Divestments stood at $139.2 million in 2022, then spiked by 313.52% to $575.4 million in 2023, then slumped by 45.35% to $314.5 million in 2024.